Violation Tracker Individual Record
Date:June 9, 2011
Offense Group:healthcare-related offenses
Primary Offense:off-label or unapproved promotion of medical products
The U.S. subsidiary of Belgian pharmaceutical manufacturer UCB SA. pleaded guilty to the off-label promotion of its epilepsy drug Keppra and will pay more than $34 million to resolve criminal and civil liability arising out of its illegal conduct.
Level of Government:federal
Action Type:agency action
Agency:Food and Drug Administration referral to the Justice Department
Civil or Criminal Case:civil and criminal
HQ Country of Parent:Belgium
Ownership Structure of Parent:publicly traded
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.